Investors Find Opportunity In Tau-Targeting Biopharmas
This article was originally published in Start Up
Tau-targeting Alzheimer's candidates, though historically rejected in favor of amyloid-beta targeting ones, have gained increasing interest from investors and larger pharma companies.
You may also be interested in...
While Forbion's new €360m venture capital fund and other investors have emerged to fund private and public companies, BARDA and other US agencies have been active supporters of biopharma firms in recent weeks. Also, KSQ grabs $80m in VC cash and VelosBios brings in $50m.
With a focus on specialty drugs, Bristol wants to be known for more than immuno-oncology. To that end, specialty development head Douglas Manion is charged with leading innovation in immunology, virology and cardiovascular, genetically defined and fibrotic disease.
START-UP reviews five years of fundraising and exit activities for privately held biopharma companies developing neurology treatments. Next month we’ll delve into neurology medtech and diagnostics companies’ capital-raising and bow-outs.